1.96
1.96 (0.69%)
As of Sep 20, 2022
Imunon, Inc. [CLSN]
Source:
Company Overview
Imunon is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.
| Country | United States |
| Headquarters | lawrenceville, new jersey |
| Phone Number | (609) 896-9100 |
| Industry | manufacturing |
| CEO | Corrine Le Goff |
| Website | www.imunon.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-19.1 |
| Net Income | $-18.6 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -117.7% |
| Profit as % of Stockholder Equity | -438.7% |
Management Effectiveness
| Return on Equity | -438.7% |
| Return on Assets | -191.6% |
| Turnover Ratio | |
| EBITA | $-19.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $9.7 |
| Total Liabilities | $5.5 |
| Operating Cash Flow | $-18.9 |
| Investing Cash Flow | $9.8 |
| Financing Cash Flow | $9.1 |
